--- title: "Definium Therapeutics Announces New Employee Inducement Grants | DFTX Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/291838819.md" description: "Definium Therapeutics announced inducement grants of 169,740 common share options to eight newly hired non-executive employees. The options, granted on July 6, 2026, vest over four years and were approved by the Compensation Committee under NASDAQ Rule 5635(c)(4) as material employment inducements." datetime: "2026-07-06T12:01:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291838819.md) - [en](https://longbridge.com/en/news/291838819.md) - [zh-HK](https://longbridge.com/zh-HK/news/291838819.md) --- # Definium Therapeutics Announces New Employee Inducement Grants | DFTX Stock News See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google Add on Google NEW YORK--(BUSINESS WIRE)--**Definium Therapeutics, Inc.** (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to eight newly hired non-executive employees consisting of options to purchase an aggregate of 169,740 common shares of the Company (the "Options") with effective grant dates of July 6, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee’s continued employment. The Options were granted as a material inducement to each employee’s employment and were approved by Definium’s Compensation Committee on June 25, 2026, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC. The Options were granted pursuant to Definium’s 2026 Inducement Plan. **About Definium Therapeutics** The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX. For more information, visit https://definiumtx.com/ and follow Definium Therapeutics on Instagram, LinkedIn and X. View source version on businesswire.com: https://www.businesswire.com/news/home/20260706280056/en/ **Investors:** Gitanjali Jain VP, Head of Investor Relations ir@definiumtx.com **Media:** media@definiumtx.com Source: Definium Therapeutics, Inc. ### Related Stocks - [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md) ## Related News & Research - [Is Definium Therapeutics (DFTX) Expensive As New GAD Study Sharpens Its Late Stage Case?](https://longbridge.com/en/news/293649367.md) - [Definium Therapeutics issues options for 30,330 shares to new hires under inducement plan](https://longbridge.com/en/news/293249267.md) - [08:46 ETHTX Research Examines RWA and DeFi: Two Separate Tracks Converging into One Financial Loop](https://longbridge.com/en/news/293935104.md) - [XRP price prediction 2026-2032: Will XRP reach $5?](https://longbridge.com/en/news/294224732.md) - [Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NKTR Stock News](https://longbridge.com/en/news/293794362.md)